// App-Quantinova.ai

: NTP42, an antagonist of the thromboxane receptor, attenuates experimentally-induced pulmonary arterial hypertension

Researchers

Presenter

  • B. Therese Kinsella

Principal Investigators

  • Eamon Mulvaney

  • Helen Reid

Medical Centers

  • ATXA Therapeutics Ltd, University College Dublin, Dublin, Ireland

Locations

  • Ireland

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Pulmonary arterial hypertension

  • Venous thrombosis

Biomarkers

  • Thromboxane A2 Receptor

Drug/Treatment

  • Monocrotaline

  • Sildenafil citrate

  • Selexipag

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved